Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

48.47 -0.84 (-1.70%)
Streaming Delayed Price Updated: 12:04 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma
FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead. 
Via MarketBeat
Why This Biotech Stock Just Doubled In A Single Day
Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
Why Is Cidara Therapeutics Stock Trading Higher On Monday?
Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3. 
Via Benzinga
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results. 
Via Benzinga
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation. 
Via Stocktwits
Topics Supply Chain
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)
From Brodsky & Smith LLC
Via GlobeNewswire
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development. 
Via MarketBeat
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial
Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance
The American Pharmacists Association announced Monday it will withhold endorsement of the CDC's updated immunization schedule. 
Via Benzinga
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition. 
Via Investor's Business Daily
Topics Government
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)
From Brodsky & Smith LLC
Via GlobeNewswire
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color. 
Via Benzinga
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
Via Benzinga
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates. 
Via Benzinga
Topics Bankruptcy
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.